|Academician Chen Wei: Nebulized and inhaled new crown vaccine is applying for emergency use|
The 2021 Pujiang Innovation Forum hosted by the Ministry of Science and Technology and the Shanghai Municipal Government held a plenary session on June 3.
Chen Wei , academician of the Chinese Academy of Engineering, attended and delivered a speech entitled "Insist on self-reliance and self-reliance, and improve the biosafety technology innovation system".
The new drug clinical application was submitted on March 9, 2020, the clinical trial was officially started on March 16, the first clinical data of the new crown vaccine was published in the world on May 22, and the vaccine was approved by the Food and Drug Administration on February 25 this year.
…"This is the first genetically engineered vaccine approved in our country, and it is currently the only single-dose new crown vaccine.
" Academician Chen Wei recalled the development and marketing of recombinant new crown virus vaccines.
"The first shot of the new crown vaccine was given to Wuhan, which gave us a lot of confidence in scientific research.
" She sighed.
In her view, strong scientific research confidence comes from years of accumulation and the country's continuous investment in science and technology.
"2018 marks the 40th anniversary of our country's implementation of the immunization plan.
We made 1 billion doses of domestic vaccines each year and achieved self-sufficiency.
Domestic vaccines have played an irreplaceable role in the entire planned immunization and prevention and control of infectious diseases.
" Chen Wei said.
At the same time, the rapid development of a new coronavirus vaccine is inseparable from the country's continuous investment in science and technology.
She introduced that the Ministry of Science and Technology has invested a lot of funds to support vaccine research and development since the "863 Program".
"The adenovirus vaccine we are currently making was funded by '863' in 2003, and we have been working on it since Ebola.
" She explained that the adenovirus vector is similar to a rocket, and the vaccine to be used is equivalent to What spacecraft do you want to carry? With this rocket, launching any spacecraft is much easier.
Regarding the impact of the virus mutation on the vaccine, which is of great concern to the public, Chen Wei said that the South African strain has a greater impact on the vaccine.
His team is also conducting clinical applications for the South African strain, hoping to enhance the immunity of the vaccine through the mutant strain.
Variant strain coverage.
Chen Wei also mentioned that his team is studying dual non-vaccine, that is, non-injection, non-cold chain vaccine.
"Now vaccination is through injection, but in fact, it can also be inoculated by other methods, such as nebulized inhalation.
We published the first non-injection vaccine research results in August last year.
A clinical trial was conducted in Wuhan on September 29 last year.
She explained that the nebulized inhalation vaccine only needs one-fifth of the dose of the injection vaccine, and the bottleneck problem of the vaccine bottle can be solved without the need to bottle one.
"If the vaccine is inhaled, it will still have mucosal immunity.
" Chen Wei said, "The Food and Drug Administration has approved the approval for the expansion of clinical trials, and we are now applying for emergency use.
According to the data, the so-called nebulized inhalation immunity is the use of a nebulizer to atomize the vaccine into tiny particles, which enter the respiratory tract and lungs through breathing inhalation, thereby stimulating mucosal immunity, which cannot be brought by intramuscular injection.
Normally, the new crown vaccine injected intramuscularly can only induce humoral and cellular immunity.
In addition, the use of aerosolized inhalation method for immunization is painless and has higher accessibility.